Innovator drug developer Genentech, maker of the biologic therapies Avastin (bevacizumab) and Rituxan (rituximab), faces challenges from biosimilar developers in the United States and abroad. This week saw developments in cases concerning both molecules in US and Japanese courts of law.
Innovator drug developer Genentech, maker of the biologic therapies Avastin (bevacizumab) and Rituxan (rituximab), faces challenges from biosimilar developers in the United States and abroad. This week saw developments in cases concerning both molecules in US and Japanese courts of law.
Genentech Holds That Amgen Infringed on Avastin Patents With Mvasi
On Thursday, a California federal judge paused Amgen’s lawsuit that sought to invalidate 27 patents covering Genentech’s innovator bevacizumab, Avastin. The judge will await further action in another case, filed by Genentech, in a Delaware district court.
In October 2017, Amgen filed its California lawsuit, seeking a judgment that Amgen’s FDA-approved bevacizumab biosimilar, Mvasi, did not and will not infringe on the 27 patents at issue for Genentech’s Avastin. It also claimed that it had complied with the information exchange process provided for under the Biologics Price Competition and Innovation Act (BPCIA). Amgen argued that not only did Genentech fail to state a claim on which relief can be granted, but it also mischaracterized Amgen’s statements concerning when it may begin marketing Mvasi.
Genentech, for its part, filed a patent infringement lawsuit against Amgen in a Delaware district court, saying that the biosimilar developer did not provide information required by the BPCIA, other than its abbreviated Biologics License Application, to Genentech, and that Amgen refused to negotiate the scope of litigation concerning patent infringement.
Genentech Sues Sandoz and Kyowa Hakko Kirin Over Rituximab
Genentech has also filed suit against Novartis division Sandoz in a Tokyo District Court, according to The Pharma Letter. Genentech has alleged that the biosimilar developer has infringed on 3 of its patents for Rituxan.
Sandoz’s biosimilar (Rixathon, Riximyo) was approved by Japan’s Ministry of Health, Labor and Welfare in September 2017. In January 2016, Sandoz entered into an exclusive license agreement with Kyowa Hakko Kirin for the distribution and promotion of its biosimilar in the Japanese market.
Under the terms of the agreement, Kyowa Hakko Kirin paid Sandoz an up-front fee and subsequent payments for the regulatory filing and approval of the drug, and will take responsibility for all sales, marketing, and promotional activities within Japan.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.